seen from Sweden
seen from Malaysia
seen from China
seen from United States
seen from China
seen from Brazil
seen from Brazil
seen from Brazil
seen from United Kingdom
seen from China
seen from United States
seen from Netherlands
seen from Italy
seen from Hong Kong SAR China
seen from United States
seen from Spain
seen from China
seen from China
seen from Malaysia
seen from Malaysia
I've just sneaked into the Monastery library and replaced most of their books with Hans' collection of somewhat bawdy poems and I can foresee a savage reading session for those monks 😏
(I unfortunately don't know the source for the pic, if anyone does, please let me know!!!)
😋👉👈
Audentes fortuna iuvat. - Štěstí přeje těm, kteří mají odvahu.
Přísloví má ekvivalenty i v jiných jazycích. Zde je několik příkladů: – V italštině: “Fortis Fortuna Adiuvat” – Toto italské přísloví znamená “štěstěna přeje statečným”. Vyjadřuje podobnou myšlenku jako latinské přísloví. – V francouzštině: “La fortune sourit aux audacieux” – Toto francouzské přísloví znamená “štěstí (štěstěna) se usmívá na odvážné”. – V angličtině: “Fortune favors the bold” –…
ASTELLAS PHARMA PLUNGES INTO GENE THERAPY WITH $3 BILLION AUDENTES ACQUISITION Astellas ( OTCMKTS: ALPMY ) has announced is acquiring Audentes Therapeutics ( NASDAQ: BOLD ) for $3 billion and plunge into the gene therapy market. Based in San Francisco, Audentes is a clinical stage research company centering on development of AAV-based genetic medicines for people with significant and rare neuromuscular diseases. Astellas, based in Tokyo, Japan with a U.S. headquarters in Northbrook, Illinois, is Japan’s second largest pharmaceutical company ( Takeda is ranked #1 ). The product portfolio of Astellas is defined by 4 categories; the addition of Audentes will establish a 5th with the specialty of genetic therapy: -Immuno-Oncology -Immunotherapy -Neuro-Muscular -Regenerative -Genetic Therapy Audentes' adeno-associated virus ( AAV ) gene therapy technology platform and proprietary production process expertise is applied in programs spanning 3 modalities: -Gene Replacement -Vectorized Exon Skipping -Vectorized RNA Knockdown Presently, the leading candidate for approval in the Auduentes portfolio is AT312 which may happen as early as mid-2020. Its clinical trials have generated good results in the treatment of X-linked myotubular myopathy (XLMTM) occurring primarily in male infants. READ MORE about how Astellas and Audentes will compete with blue chip pharmaceutical manufacturers like Roche, Pfizer and Novartis in the rapidly expanding gene therapy market sector...
Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)
Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)
Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) said on Friday that the board of directors’ compensation committee awarded equity awards to six newly appointed individuals in accordance with Nasdaq Listing Rule 5635(c)(4).
On the grant date of 7 March 2019, the employees received, in the aggregate, options to purchase 14,600 common stock from the company. The options have an…
View On WordPress
Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)
Audentes Therapeutics grants stock options to six new employees under Nasdaq Listing Rule 5635(c)(4)
Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) said on Friday that the board of directors’ compensation committee awarded equity awards to six newly appointed individuals in accordance with Nasdaq Listing Rule 5635(c)(4).
On the grant date of 7 March 2019, the employees received, in the aggregate, options to purchase 14,600 common stock from the company. The options have an…
View On WordPress
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $ 40.00
Feb 25, 2019 (Market Exclusive via COMTEX) —
Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD)
Today, Audentes Therapeutics Inc (NASDAQ:BOLD) stock received an upgrade by Chardan Capital from Neutral to Buy with a price target of $…
View On WordPress
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $40.00
Audentes Therapeutics Inc (NASDAQ:BOLD) gets upgraded to Buy by Chardan Capital with a price target of $ 40.00
Feb 25, 2019 (Market Exclusive via COMTEX) —
Analyst Ratings For Audentes Therapeutics Inc (NASDAQ:BOLD)
Today, Audentes Therapeutics Inc (NASDAQ:BOLD) stock received an upgrade by Chardan Capital from Neutral to Buy with a price target of $…
View On WordPress
